Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection

scientific article

Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P698PubMed publication ID19649930

P2093author name stringDavid Durantel
P433issue8
P304page(s)860-870
P577publication date2009-08-01
P1433published inCurrent Opinion in Investigational DrugsQ15724634
P1476titleCelgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection
P478volume10

Reverse relations

cites work (P2860)
Q35676012A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue)
Q40368500Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor.
Q38118461Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions
Q38159719Bitter-sweet symphony: glycan-lectin interactions in virus biology
Q29994527Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Q33930289Comparative Analysis of Protein Glycosylation Pathways in Humans and the Fungal Pathogen Candida albicans
Q26828727Curing a viral infection by targeting the host: the example of cyclophilin inhibitors
Q28542607Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions
Q34306359Diastereoselective Nitrenium Ion-Mediated Cyclofunctionalization: Total Synthesis of (+)-Castanospermine
Q47558474Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo
Q26257542Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients
Q53683152Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies.
Q34235286Hepatitis C virus experimental model systems and antiviral drug research
Q26779128Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection
Q55280981Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
Q34403294Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay
Q37584342Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents
Q94561396Iminosugars With Endoplasmic Reticulum α-Glucosidase Inhibitor Activity Inhibit ZIKV Replication and Reverse Cytopathogenicity in vitro
Q35191986In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4.
Q41687420Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.
Q39617748Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release
Q38597477Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase : synthesis, structure-activity relationship studies and antiviral activity.
Q59360239Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus
Q89725380Medicinal chemistry strategies toward host targeting antiviral agents
Q34130399New antiviral therapies for chronic hepatitis C
Q38238424New pharmacological strategies to fight enveloped viruses
Q90669855Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C
Q34576190Potential treatment options and future research to increase hepatitis C virus treatment response rate
Q40251429Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses
Q42279828Steviamine, a new class of indolizidine alkaloid [(1R,2S,3R,5R,8aR)-3-hydroxy-meth-yl-5-methyl-octa-hydro-indolizine-1,2-diol hydro-bromide].
Q90737186Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus
Q38615654Targeting HCV entry for development of therapeutics
Q37699395Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.
Q35656099Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections
Q37666750West Nile virus drug discovery

Search more.